Analysts Offer Predictions for BOLT Q1 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Equities researchers at Leerink Partnrs issued their Q1 2026 EPS estimates for Bolt Biotherapeutics in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings of ($0.36) per share for the quarter. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS and Q4 2026 earnings at ($0.16) EPS.

Several other brokerages also recently commented on BOLT. Stifel Nicolaus dropped their target price on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a report on Tuesday. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Trading Up 4.8 %

NASDAQ:BOLT opened at $0.44 on Thursday. Bolt Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.56. The business’s 50-day moving average is $0.47 and its two-hundred day moving average is $0.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The firm has a market capitalization of $16.84 million, a PE ratio of -0.26 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Monday, March 24th. The company reported ($0.38) EPS for the quarter, meeting analysts’ consensus estimates of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.79 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter valued at approximately $25,000. Squarepoint Ops LLC acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at approximately $26,000. Velan Capital Investment Management LP purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at approximately $27,000. Citadel Advisors LLC acquired a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $42,000. Finally, FMR LLC increased its stake in shares of Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares during the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.